173 related articles for article (PubMed ID: 22767140)
1. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Tanaka H; Nakashima S; Usuda M
Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
[TBL] [Abstract][Full Text] [Related]
2. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
[TBL] [Abstract][Full Text] [Related]
3. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
Kreutzman A; Ladell K; Koechel C; Gostick E; Ekblom M; Stenke L; Melo T; Einsele H; Porkka K; Price DA; Mustjoki S; Seggewiss R
Leukemia; 2011 Oct; 25(10):1587-97. PubMed ID: 21647156
[TBL] [Abstract][Full Text] [Related]
4. Large granular lymphocytosis during dasatinib therapy.
Qiu ZY; Xu W; Li JY
Cancer Biol Ther; 2014 Mar; 15(3):247-55. PubMed ID: 24352048
[TBL] [Abstract][Full Text] [Related]
5. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
Nagata Y; Ohashi K; Fukuda S; Kamata N; Akiyama H; Sakamaki H
Int J Hematol; 2010 Jun; 91(5):799-807. PubMed ID: 20405252
[TBL] [Abstract][Full Text] [Related]
6. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
[TBL] [Abstract][Full Text] [Related]
7. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
[TBL] [Abstract][Full Text] [Related]
8. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib.
Breccia M; Latagliata R; Stagno F; Luciano L; Gozzini A; Castagnetti F; Fava C; Cavazzini F; Annunziata M; Russo Rossi A; Pregno P; Abruzzese E; Vigneri P; Rege-Cambrin G; Sica S; Pane F; Santini V; Specchia G; Rosti G; Alimena G
Haematologica; 2011 Oct; 96(10):1457-61. PubMed ID: 21685471
[TBL] [Abstract][Full Text] [Related]
9. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
Breccia M; Alimena G
Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
Paydas S
Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
Hochhaus A
Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
[TBL] [Abstract][Full Text] [Related]
12. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Sillaber C; Herrmann H; Bennett K; Rix U; Baumgartner C; Böhm A; Herndlhofer S; Tschachler E; Superti-Furga G; Jäger U; Valent P
Eur J Clin Invest; 2009 Dec; 39(12):1098-109. PubMed ID: 19744184
[TBL] [Abstract][Full Text] [Related]
14. Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib.
Hayashi Y; Nakamae H; Katayama T; Nakane T; Koh H; Nakamae M; Hirose A; Hagihara K; Terada Y; Nakao Y; Hino M
Leuk Lymphoma; 2012 Jun; 53(6):1084-9. PubMed ID: 22211798
[TBL] [Abstract][Full Text] [Related]
15. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia.
Kumagai T; Matsuki E; Inokuchi K; Ohashi K; Shinagawa A; Takeuchi J; Yoshida C; Okamoto S; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Nishiwaki K; Oba K; Sakamoto J; Sakamaki H
Int J Hematol; 2014 Jan; 99(1):41-52. PubMed ID: 24297450
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib-induced pleural effusions: a lymphatic network disorder?
Goldblatt M; Huggins JT; Doelken P; Gurung P; Sahn SA
Am J Med Sci; 2009 Nov; 338(5):414-7. PubMed ID: 19838099
[TBL] [Abstract][Full Text] [Related]
17. Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia.
Lee SJ; Jung CW; Kim DY; Lee KH; Sohn SK; Kwak JY; Kim HJ; Kim IH; Park S; Kim DH
Am J Hematol; 2011 Apr; 86(4):346-50. PubMed ID: 21442637
[TBL] [Abstract][Full Text] [Related]
18. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
Kim DH; Kamel-Reid S; Chang H; Sutherland R; Jung CW; Kim HJ; Lee JJ; Lipton JH
Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
20. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
